Patents by Inventor Edgar Raymond Wood, III

Edgar Raymond Wood, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150366868
    Abstract: A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.
    Type: Application
    Filed: August 21, 2015
    Publication date: December 24, 2015
    Applicant: NOVARTIS AG
    Inventors: Karen Elizabeth Lackey, Robert J. Mullin, Neil Spector, Edgar Raymond Wood, III, Wenle Xia
  • Patent number: 8444988
    Abstract: A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: May 21, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Karen Elizabeth Lackey, Robert J. Mullin, Neil Spector, Edgar Raymond Wood, III, Wenle Xia
  • Publication number: 20120058113
    Abstract: A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.
    Type: Application
    Filed: November 11, 2011
    Publication date: March 8, 2012
    Inventors: Karen Elizabeth Lackey, Robert J. Mullin, Neil Spector, Edgar Raymond Wood, III, Wenle Xia
  • Publication number: 20110312982
    Abstract: A method of treating cancer is described including administration of a 4-quinazolinamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolinamines.
    Type: Application
    Filed: September 1, 2011
    Publication date: December 22, 2011
    Inventors: Karen Elizabeth Lackey, Robert J. Mullin, Neil Spector, Edgar Raymond Wood, III, Wenle Xia
  • Publication number: 20100249160
    Abstract: A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.
    Type: Application
    Filed: June 15, 2010
    Publication date: September 30, 2010
    Inventors: Karen Elizabeth Lackey, Robert J. Mullin, Neil Spector, Edgar Raymond Wood, III, Wenie Xia
  • Patent number: 7338966
    Abstract: The present invention is related to oxindole derivatives of structure (I), compositions containing the same, and methods of use and manufacture of the same. Such compounds generally are useful pharmacologically as agents in those disease states alleviated by the alteration of mitogen activated signaling pathways in general, and in particular in the inhibition or antagonism of protein kinases, which pathologically involve aberrant cellular proliferation. Such disease states include tumor growth, restenosis, atherosclerosis, pain and thrombosis. In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit Trk family protein tyrosine kinase inhibition, and which are useful in cancer therapy and chronic pain indications.
    Type: Grant
    Filed: June 9, 2005
    Date of Patent: March 4, 2008
    Assignee: SmithKline Beecham Corporation
    Inventors: Karen Elizabeth Lackey, Edgar Raymond Wood, III
  • Patent number: 7141576
    Abstract: A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as pharmaceutical combinations and compositions containing the same.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: November 28, 2006
    Assignee: SmithKline Beecham (Cork) Limited
    Inventors: Karen Elizabeth Lackey, Neil Spector, Edgar Raymond Wood, III., Wenle Xia
  • Patent number: 7071217
    Abstract: The present invention is related to oxindole derivatives of structure (I), compositions containing the same, and methods of use and manufacture of the same. Such compounds generally are useful pharmacologically as agents in those disease states alleviated by the alteration of mitogen activated signaling pathways in general, and in particular in the inhibition or antagonism of protein kinases, which pathologically involve aberrant cellular proliferation. Such disease states include tumor growth, restenosis, atherosclerosis, pain and thrombosis, In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit Trk family protein tyrosine kinase inhibition, and which are useful in cancer therapy and chronic pain indications.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: July 4, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: Scott Howard Dickerson, Robert N Hunter, Lee Frederick Kuyper, Karen Elizabeth Lackey, Michael J. Luzzio, Edgar Raymond Wood, III
  • Patent number: 7015231
    Abstract: The present invention is related to aza-oxindole derivatives, compositions containing the same, and methods of use and manufacture of the same. Such compounds generally are useful pharmacologically as agents in those disease states alleviated by the alteration of mitogen activated signaling pathways in general, and in particular in the inhibition or antagonism of protein kinases, which pathologically involve aberrant cellular proliferation. Such disease states include tumor growth, restenosis, atherosclerosis, pain and thrombosis. In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit Trk family protein tyrosine kinase inhibition, and which are useful in cancer therapy and chronic pain indications.
    Type: Grant
    Filed: September 24, 2002
    Date of Patent: March 21, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: Karen Elizabeth Lackey, Edgar Raymond Wood, III
  • Patent number: 6964977
    Abstract: The present invention is related to oxindole derivatives of structure (I), compositions containing the same, and methods of use and manufacture of the same. Such compounds generally are useful pharmacologically as agents in those disease states alleviated by the alteration of mitogen activated signaling pathways in general, and in particular in the inhibition or antagonism of protein kinases, which pathologically involve aberrant cellular proliferation. Such disease states include tumor growth, restenosis, atherosclerosis, pain and thrombosis. In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit Trk family protein tyrosine kinase inhibition, and which are useful in cancer therapy and chronic pain indications.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: November 15, 2005
    Assignee: SmithKline Beecham Corporation
    Inventors: Philip Anthony Harris, Robert N Hunter, Robert Walton McNutt, Jr., Lee Frederick Kuyper, Karen Elizabeth Lackey, Michael Robert Peel, Edgar Raymond Wood, III